NII-21

NII-21
Name	NII-21

NII-21 NII-21 is a synthetic compound investigated for neuromodulatory and neuroprotective properties. It has been examined in preclinical and limited clinical contexts alongside investigations from institutions and investigators across neuroscience, pharmacology, and toxicology. Research into NII-21 intersects with work on neurodegeneration, psychiatry, and biodefense-related pharmacology.

Overview

NII-21 has been characterized in studies by researchers at Institute of Experimental Medicine, Institute of Pharmacology, Kovalevsky Institute, and collaborations with international centers such as Johns Hopkins University, Massachusetts Institute of Technology, Harvard Medical School, Columbia University, University of Oxford, University of Cambridge, Karolinska Institutet, Max Planck Society, Institut Pasteur, Weizmann Institute of Science, Riken, University of Tokyo, Peking University, Tsinghua University, Imperial College London, University College London, Yale School of Medicine, Stanford University School of Medicine, UCL Queen Square Institute of Neurology, McGill University, University of Toronto, University of California, San Francisco, UCSF Medical Center, University of Pennsylvania, University of Chicago, King's College London, University of Edinburgh, Monash University, Australian National University, University of Melbourne, Seoul National University, National University of Singapore, National Institutes of Health, Centers for Disease Control and Prevention, European Medicines Agency, World Health Organization, Food and Drug Administration, Defense Advanced Research Projects Agency, National Institute of Allergy and Infectious Diseases, National Institute of Neurological Disorders and Stroke, Wellcome Trust, Gates Foundation, Bill & Melinda Gates Foundation, Howard Hughes Medical Institute, and several pharmaceutical companies.

History and development

Initial synthesis and characterization of NII-21 were reported in laboratory reports associated with institutes tied to post-Soviet pharmacological research and later in collaborative publications involving researchers from Moscow State University, Saint Petersburg State University, Lomonosov Moscow State University, Russian Academy of Sciences, Pennsylvania State University, Duke University School of Medicine, Cornell University, Brown University, Vanderbilt University Medical Center, Northwestern University, University of Michigan, Ohio State University, University of Pittsburgh Medical Center, University of Minnesota, University of Wisconsin–Madison, University of California, Los Angeles, UCLA Medical Center, University of British Columbia, University of Queensland, University of Sydney, École Normale Supérieure, Sorbonne University, Université Paris Cité, Heidelberg University, Ludwig Maximilian University of Munich, Technical University of Munich, ETH Zurich, University of Zurich, University of Geneva, Karlsruhe Institute of Technology, and industry partners. Reports describe iterative medicinal chemistry optimization paralleling work on neuroactive agents studied at Eli Lilly and Company, Pfizer, GlaxoSmithKline, Roche, Novartis, Johnson & Johnson, Sanofi, AstraZeneca, Bayer, Merck & Co., Boehringer Ingelheim, Takeda Pharmaceutical Company and smaller biotech firms.

Chemical composition and mechanism of action

Analytical chemistry profiles published by collaborative analytic groups reference spectroscopic, chromatographic, and mass spectrometric characterization similar to methods used at American Chemical Society-affiliated laboratories and instrumentation cores at National High Magnetic Field Laboratory and European Molecular Biology Laboratory. Structural elucidation aligns with heterocyclic neuroactive scaffolds found in literature alongside compounds from Organon, AbbVie, and academic synthetic chemistry groups. Mechanistic proposals connect NII-21 to modulation of synaptic signaling pathways implicated in studies at Cold Spring Harbor Laboratory, Salk Institute for Biological Studies, Broad Institute, The Rockefeller University, Howard Hughes Medical Institute, and Allen Institute for Brain Science. Reported targets and pathways discussed in primary accounts parallel research on neurotransmitter receptors and ion channels studied at NINDS-funded centers, including comparisons to agents affecting pathways associated with BDNF signaling, mTOR pathway research from MIT, GSK3 modulation referenced in University of Cambridge publications, and interactions cited alongside NMDA receptor and AMPA receptor pharmacology described in publications from Yale University and University of California, San Diego.

Pharmacology and pharmacokinetics

Pharmacological profiling reported by preclinical groups used assays and in vivo models developed at Salk Institute, The Jackson Laboratory, European Bioinformatics Institute, National Center for Biotechnology Information, Institut Pasteur, Riken, Max Planck Institute of Neurobiology, and university cores. Studies describe dose–response relationships, receptor binding assays, and behavioral paradigms comparable to those used in research at University of Oxford and King's College London for neuroactive compounds. Pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion have been compared against benchmarks from studies at FDA-linked labs and analytical centers at UCLA, UCSF, Johns Hopkins University, and Cambridge University Hospitals.

Clinical research and applications

Clinical and translational interest in NII-21 has been noted in conference abstracts presented at meetings hosted by organizations including Society for Neuroscience, American Neurological Association, European Academy of Neurology, American Psychiatric Association, International Congress of Parkinson's Disease and Movement Disorders, World Congress of Neurology, American College of Neuropsychopharmacology, European College of Neuropsychopharmacology, International Neuropsychiatric Association, Federation of European Neuroscience Societies, and symposia at Cold Spring Harbor Laboratory. Investigations have explored potential applications in conditions studied at affiliated centers such as Alzheimer's Disease International-linked clinics, Michael J. Fox Foundation-funded Parkinson's research, and psychiatric trials modeled after protocols at National Institute of Mental Health, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic, and Mount Sinai Health System.

Safety, toxicity, and regulatory status

Toxicology assessments used methodologies standardized by Organisation for Economic Co-operation and Development, European Medicines Agency, Food and Drug Administration, and research safety offices at NIH, CDC, and universities including Harvard T.H. Chan School of Public Health. Reported safety signals have prompted reviews by institutional review boards and regulatory bodies at institutes such as Roszdravnadzor-linked laboratories, Ministry of Health of the Russian Federation, and international regulators referenced at EMA and FDA. Preclinical toxicity datasets were compared with compounds profiled in repositories maintained by PubChem, ChEMBL, DrugBank, Chemical Abstracts Service, and academic compound libraries at Broad Institute.

Controversies and ethical considerations

Controversies around NII-21 involve discussions at ethics committees and policy forums hosted by World Health Organization, United Nations Office for Disarmament Affairs, European Commission, Council of Europe, Human Rights Watch, Amnesty International, The Lancet, Nature, Science (journal), New England Journal of Medicine, BMJ, and academic law and bioethics centers at Harvard Law School, Yale Law School, University of Oxford Faculty of Law, Georgetown University Law Center, University of Cambridge Faculty of Law, King's College London Dickson Poon School of Law, Columbia Law School, Stanford Center for Biomedical Ethics, Kennedy Institute of Ethics, Nuffield Council on Bioethics, Wellcome Trust Sanger Institute policy groups, and national bioethics committees. Debates have referenced dual-use concerns, informed consent standards from Declaration of Helsinki signatories, data transparency advocated by Open Science Framework, and publication ethics promoted by Committee on Publication Ethics.

Category:Pharmacology